Background and Aims: An increased prevalence of irritable bowel syndrome [IBS]-like symptoms has been reported in patients with ulcerative colitis [UC]. Whether ongoing inflammation increases the prevalence of such symptoms is unknown. The aims of this study were to determine the prevalence of IBS-like symptoms in a population-based cohort of UC patients 20 years after diagnosis, and to assess the possible association between such symptoms and ongoing inflammation. Methods: Patients diagnosed with UC between 1990 and 1994, in a geographically well-defined area, were included in a prospective follow-up study, and IBS symptoms according to Rome III criteria were recorded 20 years after diagnosis. The patients underwent colonoscopy with biopsies and/or the level of faecal calprotectin was analysed. Results: A total of 260 patients answered the Rome III questionnaire. The overall prevalence of IBSlike symptoms was 27%. In patients who had no signs of inflammation in colonic biopsies [n = 96] [deep remission], the prevalence was 29%. No difference in prevalence of IBS-like symptoms was found between patients with ongoing inflammation and patients in deep remission. Conclusions: IBS-like symptoms in UC patients are frequent after 20 years of disease. Deep remission did not change the frequency of IBS-like symptoms.
Introduction
Irritable bowel syndrome [IBS] is a common disorder with a prevalence of 8.1% (95% confidence interval [CI] 7.0-8.3) in community-based studies from North America, Europe, Australia, and New Zealand. 1 Among patients with ulcerative colitis [UC] in remission, a higher prevalence of IBS-like symptoms than expected was reported more than 30 years ago by Isgar et al. 2 These findings have since been repeated in several studies in UC patients as well as in patients with Crohn's disease [CD]. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] There is however, considerable variation in the reported prevalence rates, ranging from 9% to 46% in UC patients with quiescent disease. 11, 15 This could be explained by different criteria used for remission in UC patients, different criteria for the diagnosis of IBS, or different study designs. Moreover, most of the studies included only a few patients. As far as we know there are no data from population-based studies.
The significance of inflammation in IBS-like symptoms has not been clarified, and there are some obvious methodological challenges regarding the definition of remission in UC. By using clinical remission [absence of UC symptoms], there may be an overlap in symptoms between IBS and UC. Likewise, there is no agreement on the definition of endoscopic remission. Mucosal healing [MH] may be defined as normal appearance of the mucosa, but it may also include patients with erythema, decreased vascular pattern, and mild friability. Surrogate markers of inflammation have been increasingly used in clinical practice; the most commonly used is faecal calprotectin [FC] , which correlates with endoscopic inflammation in UC. [16] [17] [18] The aims of the present study were to determine the prevalence of IBS-like symptoms in a well-defined population-based cohort of UC patients, 20 years after diagnosis, and to assess the possible association between IBS-like symptoms and ongoing inflammation.
Methods

Patients
Over a 4-year period, from January 1, 1990 to December 31, 1993 , all new patients with IBD were recorded in four geographically well-defined areas in south-eastern Norway [the IBSEN study]. This cohort has been followed prospectively, with follow-up at 1, 5, 10, and 20 years after diagnosis. The organisation of the study and the diagnostic criteria have been described in detail elsewhere. 19 The 20-year visit included a structured interview, clinical examination, and laboratory tests [including FC]. Unless they objected to the procedure, the patients underwent colonoscopy with biopsies from the colon and rectum. Patients who underwent colectomy during the follow-up period were excluded from the study.
A total of 843 cases of inflammatory bowel disease [IBD] were identified during the registration period. After 20 years of follow-up, 402 patients were alive and had a definite UC diagnosis; of these, 274 patients were available for follow-up in our study [ Figure 1 ].
Evaluation of inflammation
The Mayo endoscopic subscore [MES] was used for classification of inflammation. 20 A Mayo score of: 0 = normal mucosa; 1 = mild disease [erythema, decreased vascular pattern, mild friability]; 2 = moderate disease [marked erythema, lack of vascular pattern, friability, erosions]; and 3 = severe disease [spontaneous bleeding, ulceration].
The histological specimens were evaluated by experienced pathologists. The maximal extent of inflammation during the followup period was classified according to the Montreal classification. 21 Patients were classified according to MES, and if endoscopy was not performed, patients were classified according to FC level. Consequently, the following categories were applied:
Category A: patients with MES 0 or 1, or FC < 250 mg/kg; Category B: patients with MES 0, or FC < 100 mg/kg; Category C: patients with normal histology on biopsies from colon and rectum [deep remission]. Patients with MES 2 and 3 or FC > 250 mg/kg were considered to have ongoing inflammation.
Evaluation of symptoms
The presence of IBS-like symptoms was evaluated according to the Rome III criteria. 22 The patients completed the Rome III questionnaire during the 20-year follow-up visit. All subtypes of IBS were included, and we did not separate into subcategories.
Statistical analysis
Descriptive statistics are expressed as the mean and range or as frequency counts or percentages. Data were analysed by Pearson´s chi-square test. The level of statistical significance was set to 5%. All the statistical analyses were performed with IBM SPSS statistics version 22.
Ethical requirements
The study was approved by the regional ethics committee. All patients provided signed informed consent. In category A, no difference was found in gender, Montreal classification, medication, or current smoking between patients reporting IBS-like symptoms and those who did not. However, patients reporting IBS-like symptoms were significantly younger [ Table 2 ]. 
Results
Of
Discussion
In this population-based inception cohort study, a high prevalence of IBS-like symptoms in UC patients in remission determined by endoscopy, FC, and histology was found after 20 years of the disease course. The prevalence of IBS-like symptoms was comparable in UC patients in remission and those with ongoing inflammation. As far as we know, this is the first study reporting on IBS-like symptoms in UC patients classified as being in deep remission, i.e. with normal histology. IBS-like symptoms are reported to be more frequent in UC patients with ongoing inflammation. In a meta-analysis by Halpin and Ford, 23 the pooled prevalence in UC patients was 36.0% [95% CI 25.047.0%] and the prevalence in UC patients in remission was 31% [95% CI 21.0%43.0%]. The authors noted a significant heterogeneity between the studies. In our study, the prevalence of IBS-like symptoms in UC patients was 27% and not significantly different from the prevalence found in the meta-analysis. In patients with ongoing inflammation, the prevalence was 35% and, in patients in remission, the prevalence was 25-30% depending on the criteria used for defining remission.
For patients in clinical remission, however, the influence of lowgrade mucosal inflammation on the prevalence of IBS-like symptoms remains unknown. Some studies have indicated that IBS-like symptoms may reflect low-grade inflammation even in patients thought to be in clinical remission. Keohane et al. 7 found a significantly higher FC level in UC patients reporting IBS-like symptoms compared with those who did not. However, the definition of remission was less strict and was based upon previous disease history, symptoms, C-reactive In another study of patients with quiescent UC, the tumour necrosis factor [TNF] alpha mRNA expression in colonic biopsies was significantly higher in UC patients with IBS-like symptoms compared with those without such symptoms. 4 This study included only 18 patients who required colonoscopy for the purpose of IBD in remission and met several criteria, including endoscopically normal mucosa. A recent study, including 132 patients with MES 0, found no difference in FC between patients who reported IBS-like symptoms and those who did not. 24 However, patients with IBS-like symptoms had higher levels of serum cytokines and poorer psychological well-being. Whether an increased level of cytokines indicates lowgrade inflammation despite low FC is not clear.
In our study, however, inflammation did not seem to influence the prevalence of IBS-like symptoms. Even when the histological findings from colonic biopsies showed no signs of inflammation, the prevalence of IBS-like symptoms was not different from that in patients with ongoing inflammation. Therefore, explanations other than inflammation should be considered to explain the increased prevalence of IBS-like symptoms in UC. Both UC and CD are more common in patients with a previous diagnosis of IBS. 25 In some patients, this might be due to a misdiagnosis of IBD, but common pathogenesis may also explain the co-existence of IBD and IBS. Infectious gastroenteritis may be a factor, since it is associated with the risk of both IBS and IBD. [25] [26] [27] The high prevalence of IBS-like symptoms in IBD may be a consequence of inflammation induced by alterations in gut physiology. Acute severe as well as chronic active UC may induce dysmotility in the gut. 28 However, colonic propulsive activity in UC patients in remission was almost normal in one study investigating this phenomenon. 29 It is also possible that hypersensitivity in the gut induced by chronic inflammation may induce symptoms; however, studies in this field are missing. Increased mucosal permeability has been reported in IBD and in IBS patients, as well as disturbed microbiota. [30] [31] [32] [33] A role of psychological distress in IBD patients has also been put forward to explain the increased prevalence of IBS. There are, however, very few data in this area.
A strength of our study is the population-based design and that patients are diagnosed according to well-established criteria. The diagnosis of UC may in some cases be difficult and, in our study, patients who initially were misdiagnosed with UC were excluded from the cohort during follow-up. Moreover, the patients had been followed for a considerable and identical time period. Whether the long observation period influenced the prevalence of IBS in any direction is not known.
This study also has some weaknesses. IBS-like symptoms were only evaluated at the 20-year follow-up in the IBSEN study. The prevalence of IBS for the entire observation period may therefore be higher than the prevalence found in our study. Not all our patients underwent colonoscopy, and some patients were classified as in remission according to the level of FC. However, we consider our definition of disease remission and classification of disease activity to be acceptable since a high level of FC [above 250 mg/kg] is shown to be significantly associated with mucosal inflammation. 16 In another study, FC level below 96 mg/kg had high sensitivity and specificity when defining MES 0. 18 According to these studies, the cut-off level of FC was set to 250 mg/kg in Category A and 100 mg/kg in Category B.
Since this study was planned and initiated, new criteria for IBS [Rome IV] were introduced in 2016. Hence, the Rome III criteria used in our study make direct comparison with future studies impossible.
Identifying patients with IBS-like symptoms is crucial in IBD followup. Avoidance of unnecessary medical treatment with potential serious side effects is important. In patients with IBS who are otherwise healthy, a low FODMAP diet improves symptoms. 34 In a recent publication, a low FODMAP diet was found to be effective in reducing symptoms in IBD patients with functional-like gastrointestinal symptoms. 35 Results from prospective randomised controlled trials in UC patients with IBSlike symptoms is missing and should be of great interest.
In conclusion, IBS-like symptoms in UC patients are frequently reported after 20 years of disease. Ongoing inflammation does not seem to influence the prevalence of such symptoms.
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